Voronoi: Deep Losses and Minimal Revenue Meet a Share Price Well Below Its 52-Week High

Thesis

The data supports a picture of a development-stage company with large losses and lumpy, small revenue. Trailing twelve-month revenue to H1 2026 was ₩4.2B, while operating income was -₩81.0B and net income was -₩69.1B. Losses have widened each year since 2022. The market cap of ₩2.3T is very large relative to these figures, with a price-to-sales ratio of 556.2 and a price-to-book ratio of 33.5. The data does not show pipeline details, trial results or partnership terms, so it cannot explain why the market values the company this way. The shares are 66.5% below the 52-week high of ₩375,500 and 29.1% above the 52-week low of ₩97,500, which points to high volatility. Investor flow, foreign ownership and short-balance data are not available.

Business overview

Voronoi (보로노이) was founded on 2015-02-24 and listed on KOSDAQ on 2022-06-24. It is classified as Biotech & Pharma and has 18,388,449 listed shares. Revenue history is irregular: ₩9.8B in 2022, zero in 2023 and 2024, and ₩7.5B in 2025. The data does not say what the revenue sources were. No recent news headlines are available in the data.

Financial analysis

These figures come from filed financial statements (DART). Operating losses were ₩17.9B in 2022, ₩31.3B in 2023, ₩36.3B in 2024 and ₩54.4B in 2025. Net losses followed the same path: ₩19.9B, ₩36.8B, ₩32.6B and ₩42.7B. On a trailing basis to H1 2026, the operating margin was -1947.1% and the net margin was -1661.0%. Return on equity was -102.0%. Liabilities to equity stood at 93.3%. Cash was ₩24.8B against trailing free cash flow of -₩92.5B, which implies a short cash runway at the current burn rate unless funding is raised. Borrowings data is not available, though a recent filing mentions convertible bonds.

Valuation

Price-to-earnings and EV/EBITDA are not meaningful because earnings are negative. Price-to-book is 33.5, down from 38.5 at the end of 2025, and price-to-sales is 556.2. Enterprise value is about ₩2.29T. Among the listed peers, price-to-book ranges from 2.2 for Celltrion to 23.0 for Alteogen, and HLB sits at 16.9. Voronoi's 33.5 is above all of them. Peer P/E ratios of 25.5 to 63.9 (HLB has none) come from profitable companies, which makes them a weak comparison. The peers are also much larger, with market caps of ₩5.8T to ₩85.5T. No dividend is paid.

Catalysts

• An investor relations event is scheduled for 2026-10-13, following another on 2026-09-17.
• On 2026-10-08 the company filed a decision to acquire its own convertible bonds before maturity, which may affect its debt and funding picture.
• A series of amended major management matter filings between 2026-09-07 and 2026-09-18 suggests ongoing corporate actions, though the data does not give their content.
• Stock option grant filings on 2026-09-09 and 2026-09-10 could matter for management incentives and share dilution.
• A 5%+ holding report was filed on 2026-08-31, and an amended half-year report on 2026-10-02.

Risks

• Cash of ₩24.8B is small compared with trailing free cash flow of -₩92.5B, so further financing may be needed.
• Revenue is small and irregular, falling to zero in 2023 and 2024, which leaves little earnings support.
• The price-to-book ratio of 33.5 is well above that of every listed peer, which leaves the shares sensitive to shifts in sentiment.
• The shares fell 13.2% in one month and 15.6% in three months, and they sit far below the 52-week high.
• Investor flow, short-selling and foreign ownership data are not available, and so is news, which limits visibility into who is trading the stock.

Closing view

The filed data shows a company with widening losses, little revenue and a limited cash balance, yet with a market value of about ₩2.3T. That gap means the valuation depends on factors outside these statements, such as pipeline progress, which the data does not cover. Recent filings point to active capital and corporate management, including a convertible bond decision, but their details are not in the data. Readers should weigh the high volatility and funding needs against the market's apparent confidence in the company's future, while recognizing the data cannot settle that question.

Model estimate of fair value

The valuation model has no estimate for this company yet (not enough data, or no positive value with the base case).

Report history

1. Oct 13, 2026InitiationVoronoi: Deep Losses and Minimal Revenue Meet a Share Price Well Below Its 52-Week High